Table 2: NIPPV tolerability comparing younger vs. older adults.

Primary and Secondary outcomes

Younger adults (64 or younger)

N (%)

Older adults (65 or older)

N (%)

All, N (%)

P-Value

Number of subjects

41 (23)

137 (77)

178

 

Willingness to use NIPPV

Ongoing NIPPV use

31 (76)

75 (55)

106 (60)

0.02

Future NIPPV use

34 (83)

95 (70)

129 (73)

0.10

Symptom relief

Improve breathing

37 (90)

114 (83)

151 (85)

0.27

Improve sleep

28 (68)

70 (51)

98 (55)

0.052

Improve alertness

21 (51)

55 (40)

76 (43)

0.21

Felt better overall

37 (90)

100 (73)

137 (77)

0.02

Discomfort and anxiety

Mask discomfort

17 (41)

94 (69)

111 (62)

0.002

Worsen anxiety

7/9 (78)

34/44 (77)

41/53 (77)

0.99

ADL limitations

Movement limitations

20 (49)

62 (45)

82 (46)

0.69

Eating limitations

26 (63)

82 (60)

108 (61)

0.68

Talking limitations

26 (63)

94 (69)

120 (67)

0.533